Ongoing clinical studies explore additional therapeutic indications, including idiopathic pulmonary fibrosis, systemic sclerosis, and other autoimmune diseases characterized by ROCK2-driven fibrosis [12,47,91,128]. This evidence concerns the gene ROCK2 and idiopathic pulmonary fibrosis.